Effect of VEGF on retinal microvascular endothelial hydraulic conductivity: the role of NO

Invest Ophthalmol Vis Sci. 2000 Dec;41(13):4256-61.

Abstract

Purpose: Vascular endothelial growth factor (VEGF) increases microvascular permeability in vivo and has been hypothesized to play a role in plasma leakage in diabetic retinopathy. Few controlled studies have been conducted to determine the mechanism underlying the effect of VEGF on transport properties (e.g., hydraulic conductivity [Lp]). This study was conducted to determine the effect of VEGF on bovine retinal microvascular endothelial LP and the role of nitric oxide (NO) and the guanylate cyclase/guanosine 3', 5'-cyclic monophosphate/protein kinase G (GC/cGMP/PKG) pathway downstream of NO in mediating the VEGF response.

Methods: Bovine retinal microvascular endothelial cells (BRECs) were grown on porous polycarbonate filters, and water flux across BREC monolayers in response to a pressure differential was measured to determine endothelial LP RESULTS: VEGF (100 ng/ml) increased endothelial LP: within 30 minutes of addition and by 13.8-fold at the end of 3 hours of exposure. VEGF stimulated endothelial monolayers to release NO and incubation of the BRECs with the nitric oxide synthase inhibitor N(G)-monomethyl-L-arginine (L-NMMA; 100 microM) significantly attenuated the VEGF-induced LP increase. It was observed that incubation of the monolayers with the GC inhibitor LY-83583 (10 microM) did not alter the VEGF-mediated LP: response. Addition of the cGMP analogue 8-br-cGMP (1 mM) did not change the baseline LP over 4 hours. Also, the PKG inhibitor KT5823 (1 microM) did not inhibit the response of BREC LP to VEGF.

Conclusions: These experiments indicate that VEGF elevates hydraulic conductivity in BRECs through a signaling mechanism that involves NO but not the GC/cGMP/PKG pathway.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Alkaloids / pharmacology
  • Aminoquinolines / pharmacology
  • Animals
  • Biological Transport / drug effects
  • Body Water / metabolism*
  • Carbazoles*
  • Cattle
  • Cells, Cultured
  • Cyclic GMP / antagonists & inhibitors
  • Cyclic GMP / metabolism
  • Cyclic GMP-Dependent Protein Kinases / antagonists & inhibitors
  • Cyclic GMP-Dependent Protein Kinases / metabolism
  • Endothelial Growth Factors / pharmacology*
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / metabolism*
  • Enzyme Inhibitors / pharmacology
  • Guanylate Cyclase / antagonists & inhibitors
  • Guanylate Cyclase / metabolism
  • Indoles*
  • Lymphokines / pharmacology*
  • Nitrates / metabolism
  • Nitric Oxide / physiology*
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Nitric Oxide Synthase Type III
  • Nitrites / metabolism
  • Permeability / drug effects
  • Retinal Vessels / cytology
  • Retinal Vessels / drug effects
  • Retinal Vessels / metabolism*
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • omega-N-Methylarginine / pharmacology

Substances

  • Alkaloids
  • Aminoquinolines
  • Carbazoles
  • Endothelial Growth Factors
  • Enzyme Inhibitors
  • Indoles
  • Lymphokines
  • Nitrates
  • Nitrites
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • KT 5823
  • omega-N-Methylarginine
  • Nitric Oxide
  • 6-anilino-5,8-quinolinedione
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type III
  • Cyclic GMP-Dependent Protein Kinases
  • Guanylate Cyclase
  • Cyclic GMP